Announced workforce reductions and restructurings across pharma, biotech, MedTech and CROs — with the scale, region and context of each event, and a link to the primary source. A picture of where the industry is tightening.
| Company | Announced | Scale | Region | Type | Context | Source |
|---|---|---|---|---|---|---|
| Takeda | May 2025 | — | Global | Pharma | Efficiency programme streamlining operations across R&D and commercial functions. | Source ↗ |
| Bristol Myers Squibb | Apr 2025 | 6,000 | Global | Pharma | Expanded cost-savings programme targeting ~$2bn in additional savings by 2027, cutting roles across the organisation. | Source ↗ |
| Bayer | Mar 2025 | — | Global | Pharma | Continued restructuring under its "Dynamic Shared Ownership" model, reducing management layers and headcount across pharma and crop science. | Source ↗ |
| Novartis | Feb 2025 | — | Global | Pharma | Ongoing structural simplification following its "pure-play" pharma pivot and Sandoz spin-off. | Source ↗ |
| Pfizer | Jan 2025 | — | Global | Pharma | Second phase of a multi-year cost-realignment programme aiming for billions in net savings after the post-COVID revenue decline. | Source ↗ |
| Roche | Nov 2024 | — | Global | Pharma | Pipeline reprioritisation with associated headcount impacts in pharma and diagnostics. | Source ↗ |
| Sanofi | Oct 2024 | — | Global | Pharma | Reorganisation tied to the planned separation of its consumer-health business (Opella). | Source ↗ |
| Moderna | Sep 2024 | — | USA | Biotech | Announced R&D spending cuts of ~$1.1bn by 2027 amid lower COVID revenue. | Source ↗ |
| Charles River Laboratories | Aug 2024 | — | Global | CRO | Cost-cutting including site consolidations amid softer early-stage biotech demand. | Source ↗ |
| Bristol Myers Squibb | Jul 2024 | 2,200 | Global | Pharma | Initial phase of a strategic productivity initiative announced with Q2 results. | Source ↗ |
| Miltenyi Biotec | Jun 2024 | — | Germany | Biotech | Workforce reductions reported amid a broader life-science tools slowdown. | Source ↗ |
| Novavax | May 2024 | — | USA | Biotech | Restructuring to cut R&D and G&A spend after COVID-vaccine demand fell. | Source ↗ |
| Illumina | Apr 2024 | — | USA | MedTech | Restructuring following the GRAIL divestiture, cutting operating costs. | Source ↗ |
| GSK | Mar 2024 | — | Global | Pharma | Selective role reductions as part of ongoing commercial and R&D prioritisation. | Source ↗ |
| Biogen | Feb 2024 | — | USA | Biotech | Continued "Fit for Growth" programme targeting ~$1bn gross savings. | Source ↗ |
| Thermo Fisher Scientific | Feb 2024 | — | Global | MedTech | Ongoing cost realignment as pandemic-era testing and bioprocessing demand normalised. | Source ↗ |
| Amgen | Jan 2024 | — | USA | Biotech | Site and role rationalisation following the Horizon Therapeutics acquisition. | Source ↗ |
| Bayer | Jan 2024 | — | Germany | Pharma | Announced significant management-layer reductions as part of organisational overhaul. | Source ↗ |
Priya Life Science (2026). Pharma & Biotech Layoffs Tracker. Available at: https://priyalifescience.com/biotech-layoffs (Accessed: 12 August 2026).
Embed this data ↗Editorially maintained from public company statements, regulatory (WARN) notices and major trade-press reporting; each row links to a primary source. Where a company discloses no headcount figure, the scale column shows "—". "Disclosed roles affected" sums only events with a public number, so the real total is higher. This tracker is informational, not a comment on any company's prospects. Related: Who's Hiring in Ireland, Company Directory, Salary Guides.